CJC 1295 No DAC 5 mg/Ipamorelin 5 mg

Product Specifications

Usage Guidelines

For Laboratory Research Only: This information summarizes scientific literature. Dragon Pharma CJC 1295 No DAC/Ipamorelin is a research chemical for in vitro or preclinical study, not for human use.

In experimental models, the blend is reconstituted with bacteriostatic water. Research often utilizes subcutaneous administration. To mimic the natural pulsatile secretion of GH, study designs frequently split the daily dose into 2-3 administrations (e.g., morning, post-training, pre-bedtime). This timing aligns with the body's natural GH surge periods. Research cycles are typically limited to 8-12 weeks to minimize potential downregulation of pituitary receptors. Administration on an empty stomach (or at least 2 hours post-meal) is common in protocols to avoid interference from food-induced insulin and somatostatin.

• Standard Pulsatile Research Cycle (8-10 weeks): Twice or thrice-daily dosing protocol to study effects on body composition, recovery markers, and sleep quality, followed by a 4-week off period.
• Extended Recovery & Anti-Aging Study (12 weeks): Longer cycle focusing on cumulative benefits for skin, joint health, and metabolic parameters, often with careful monitoring of fasting glucose.

Post Cycle Therapy (PCT):

As peptides that stimulate endogenous GH, this blend does not suppress the HPTA, so traditional PCT with Clomid is unnecessary. The primary research consideration is pituitary receptor sensitivity. A break of at least 4 weeks between cycles is standard to allow receptor recovery. Some research protocols may incorporate a GHRH like Sermorelin during the off-period to maintain gentle stimulation. For comprehensive hormonal support research post-cycle, Enclomiphene could be studied for testosterone optimization.

Synergistic Research & Support:

This GH-stimulating blend is often researched alongside other compounds for body recomposition. For studying muscle growth synergy, it can be paired with SARMs like LGD 4033. For enhanced fat loss research, combining with Tesamorelin (a different GHRH) or AOD 9604 could be explored. To support joint and connective tissue health during intense training studies, adding TB-500 may be relevant.

Third-Party Lab Tested

2025-11-07

View Result

5.93 mg/4.96 mg

Lab Analysis: The November 2025 third-party HPLC test confirms 5.93 mg of CJC 1295 (No DAC) and 4.96 mg of Ipamorelin per vial, totaling 10.89 mg with a precise 1.19:1 ratio. This demonstrates excellent batch consistency, high purity for both peptides, and accurate blending—exceeding the labeled 10 mg total content.

Storage Instructions

Proper storage is essential to preserve the stability of this peptide blend.

• Unreconstituted Powder: For long-term stability, store the sealed vial in a freezer at -20°C (-4°F) or colder. The lyophilized blend remains stable for up to 24 months under these conditions. Avoid repeated freeze-thaw cycles and protect from light.
• After Reconstitution: Once reconstituted with bacteriostatic water, the solution must be refrigerated immediately at 2°C to 8°C (36°F to 46°F). The refrigerated solution is typically viable for research for 3-4 weeks. For studies using multi-daily dosing, maintaining strict refrigeration is critical. Never freeze the reconstituted liquid.
• Important Note: Due to the differing stabilities of the two peptides, it is recommended to use the reconstituted solution within 21 days for optimal research results. Always use sterile technique.